From bench to bedside and back again: Translational research in autoinflammation

Dirk Holzinger, Christoph Kessel, Alessia Omenetti, Marco Gattorno

Research output: Contribution to journalArticle

Abstract

Translational research approaches brought major changes to the understanding and treatment options of autoinflammatory diseases. Patients with common complex multifactorial diseases such as systemic-onset juvenile idiopathic arthritis (sJIA), and particularly those with rare monogenic autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) or TNF receptor-associated periodic syndrome (TRAPS), benefited from a deeper understanding of the pathophysiological mechanisms and new treatment options emerging from preclinical studies. The study of IL-1 and IL-6 in this context led to novel therapies by forward translation. Conversely, effective treatment of sJIA and TRAPS with IL-1 blockade stimulated reverse translational efforts to study the pathophysiology of these cytokines in autoinflammatory diseases. These translational efforts led to the discovery of biomarkers such as S100 proteins, IL-18 or serum amyloid A, which are components of the inflammatory process, support diagnosis and allow for monitoring of disease activity, helping to predict patient outcomes. The ongoing characterization of autoinflammatory diseases in individual patients has led to classification into heterogeneous subgroups. Further characterization of relevant subgroups and the design of tailored treatment regimens, as well as the identification of new therapeutic targets and treatment options, are the major future challenges in the field of autoinflammatory diseases, particularly for paediatric rheumatologists.

Original languageEnglish
Pages (from-to)573-585
Number of pages13
JournalNature Reviews Rheumatology
Volume11
Issue number10
DOIs
Publication statusPublished - Oct 29 2015

Fingerprint

Translational Medical Research
Juvenile Arthritis
Interleukin-1
Therapeutics
Cryopyrin-Associated Periodic Syndromes
Serum Amyloid A Protein
Interleukin-18
S100 Proteins
Interleukin-6
Biomarkers
Pediatrics
Cytokines

ASJC Scopus subject areas

  • Rheumatology

Cite this

From bench to bedside and back again : Translational research in autoinflammation. / Holzinger, Dirk; Kessel, Christoph; Omenetti, Alessia; Gattorno, Marco.

In: Nature Reviews Rheumatology, Vol. 11, No. 10, 29.10.2015, p. 573-585.

Research output: Contribution to journalArticle

Holzinger, Dirk ; Kessel, Christoph ; Omenetti, Alessia ; Gattorno, Marco. / From bench to bedside and back again : Translational research in autoinflammation. In: Nature Reviews Rheumatology. 2015 ; Vol. 11, No. 10. pp. 573-585.
@article{eedf9ab8b50e47308883566de4564350,
title = "From bench to bedside and back again: Translational research in autoinflammation",
abstract = "Translational research approaches brought major changes to the understanding and treatment options of autoinflammatory diseases. Patients with common complex multifactorial diseases such as systemic-onset juvenile idiopathic arthritis (sJIA), and particularly those with rare monogenic autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) or TNF receptor-associated periodic syndrome (TRAPS), benefited from a deeper understanding of the pathophysiological mechanisms and new treatment options emerging from preclinical studies. The study of IL-1 and IL-6 in this context led to novel therapies by forward translation. Conversely, effective treatment of sJIA and TRAPS with IL-1 blockade stimulated reverse translational efforts to study the pathophysiology of these cytokines in autoinflammatory diseases. These translational efforts led to the discovery of biomarkers such as S100 proteins, IL-18 or serum amyloid A, which are components of the inflammatory process, support diagnosis and allow for monitoring of disease activity, helping to predict patient outcomes. The ongoing characterization of autoinflammatory diseases in individual patients has led to classification into heterogeneous subgroups. Further characterization of relevant subgroups and the design of tailored treatment regimens, as well as the identification of new therapeutic targets and treatment options, are the major future challenges in the field of autoinflammatory diseases, particularly for paediatric rheumatologists.",
author = "Dirk Holzinger and Christoph Kessel and Alessia Omenetti and Marco Gattorno",
year = "2015",
month = "10",
day = "29",
doi = "10.1038/nrrheum.2015.79",
language = "English",
volume = "11",
pages = "573--585",
journal = "Nature reviews. Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - From bench to bedside and back again

T2 - Translational research in autoinflammation

AU - Holzinger, Dirk

AU - Kessel, Christoph

AU - Omenetti, Alessia

AU - Gattorno, Marco

PY - 2015/10/29

Y1 - 2015/10/29

N2 - Translational research approaches brought major changes to the understanding and treatment options of autoinflammatory diseases. Patients with common complex multifactorial diseases such as systemic-onset juvenile idiopathic arthritis (sJIA), and particularly those with rare monogenic autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) or TNF receptor-associated periodic syndrome (TRAPS), benefited from a deeper understanding of the pathophysiological mechanisms and new treatment options emerging from preclinical studies. The study of IL-1 and IL-6 in this context led to novel therapies by forward translation. Conversely, effective treatment of sJIA and TRAPS with IL-1 blockade stimulated reverse translational efforts to study the pathophysiology of these cytokines in autoinflammatory diseases. These translational efforts led to the discovery of biomarkers such as S100 proteins, IL-18 or serum amyloid A, which are components of the inflammatory process, support diagnosis and allow for monitoring of disease activity, helping to predict patient outcomes. The ongoing characterization of autoinflammatory diseases in individual patients has led to classification into heterogeneous subgroups. Further characterization of relevant subgroups and the design of tailored treatment regimens, as well as the identification of new therapeutic targets and treatment options, are the major future challenges in the field of autoinflammatory diseases, particularly for paediatric rheumatologists.

AB - Translational research approaches brought major changes to the understanding and treatment options of autoinflammatory diseases. Patients with common complex multifactorial diseases such as systemic-onset juvenile idiopathic arthritis (sJIA), and particularly those with rare monogenic autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) or TNF receptor-associated periodic syndrome (TRAPS), benefited from a deeper understanding of the pathophysiological mechanisms and new treatment options emerging from preclinical studies. The study of IL-1 and IL-6 in this context led to novel therapies by forward translation. Conversely, effective treatment of sJIA and TRAPS with IL-1 blockade stimulated reverse translational efforts to study the pathophysiology of these cytokines in autoinflammatory diseases. These translational efforts led to the discovery of biomarkers such as S100 proteins, IL-18 or serum amyloid A, which are components of the inflammatory process, support diagnosis and allow for monitoring of disease activity, helping to predict patient outcomes. The ongoing characterization of autoinflammatory diseases in individual patients has led to classification into heterogeneous subgroups. Further characterization of relevant subgroups and the design of tailored treatment regimens, as well as the identification of new therapeutic targets and treatment options, are the major future challenges in the field of autoinflammatory diseases, particularly for paediatric rheumatologists.

UR - http://www.scopus.com/inward/record.url?scp=84943361670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943361670&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2015.79

DO - 10.1038/nrrheum.2015.79

M3 - Article

C2 - 26077920

AN - SCOPUS:84943361670

VL - 11

SP - 573

EP - 585

JO - Nature reviews. Rheumatology

JF - Nature reviews. Rheumatology

SN - 1759-4790

IS - 10

ER -